4.5 Article

Optimization of the two-stage group sequential three-arm gold-standard design for non-inferiority trials

Related references

Note: Only part of the references are listed.
Article Mathematical & Computational Biology

Sample Size Calculation for Gold-Standard Noninferiority Trials With Fixed Margins and Negative Binomial Endpoints

Gosuke Homma et al.

Summary: This study proposes a sample size calculation method for gold-standard noninferiority trials with two fixed margins and negative binomial endpoints. Through simulation, it is shown that the proposed hypothesis-testing method achieves the target power while controlling the Type I error rate at a nominal level, and that the sample size calculation method has adequate power accuracy. Additionally, an application of the proposed method in a clinical trial of mild asthma is illustrated.

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2021)

Article Mathematical & Computational Biology

Optimal planning of adaptive two-stage designs

Maximilian Pilz et al.

Summary: The study demonstrates that optimal adaptive designs can bring significant benefits in clinical trial planning. By customizing the underlying optimization problem, optimal designs can be tailored to specific operational requirements for an almost negligible performance loss compared to conventional designs.

STATISTICS IN MEDICINE (2021)

Review Health Care Sciences & Services

Most noninferiority trials were not designed to preserve active comparator treatment effects

Michael Tsui et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)

Article Mathematical & Computational Biology

A variational approach to optimal two-stage designs

Maximilian Pilz et al.

STATISTICS IN MEDICINE (2019)

Article Mathematical & Computational Biology

Sequential parallel comparison design for gold standard noninferiority trials with a prespecified margin

Gosuke Homma et al.

BIOMETRICAL JOURNAL (2019)

Article Pharmacology & Pharmacy

Group-sequential three-arm noninferiority clinical trial designs

Toshimitsu Ochiai et al.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2017)

Article Mathematical & Computational Biology

A studentized permutation test for three-arm trials in the 'gold standard' design

Tobias Muetze et al.

STATISTICS IN MEDICINE (2017)

Article Mathematical & Computational Biology

Blinded sample size re-estimation in three-arm trials with gold standard' design

Tobias Muetze et al.

STATISTICS IN MEDICINE (2017)

Article Mathematical & Computational Biology

Group sequential designs for three-arm 'gold standard' non-inferiority trials with fixed margin

Patrick Schloemer et al.

STATISTICS IN MEDICINE (2013)

Article Mathematical & Computational Biology

A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design

Kathrin Stucke et al.

STATISTICS IN MEDICINE (2012)

Article Mathematical & Computational Biology

Hierarchical testing of multiple endpoints in group-sequential trials

Ekkehard Glimm et al.

STATISTICS IN MEDICINE (2010)

Article Mathematical & Computational Biology

Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity

Mario Hasler et al.

STATISTICS IN MEDICINE (2008)

Article Mathematical & Computational Biology

Planning and analysis of three-arm non-inferiority trials with binary endpoints

Meinhard Kieser et al.

STATISTICS IN MEDICINE (2007)

Article Pharmacology & Pharmacy

Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials

H. M. James Hung et al.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2007)

Article Mathematical & Computational Biology

Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin

[Anonymous]

STATISTICS IN MEDICINE (2006)

Article Mathematical & Computational Biology

Efficient group sequential designs when there are several effect sizes under consideration

C Jennison et al.

STATISTICS IN MEDICINE (2006)

Article Mathematical & Computational Biology

Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo

I Pigeot et al.

STATISTICS IN MEDICINE (2003)